Jason Rothbart, MD
Obstetrics & Gynecology · Los Angeles, CANPI 1316944200
Payments from drug & device makers
Across 113 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$541
- Mayne Pharma Commercial LLC$468
- Exeltis, USA Inc.$152
- Coopersurgical, Inc.$137
- Astellas Pharma US Inc$134
- Therapeuticsmd, Inc.$128
- plus $553 from 16 others
What the payments were for
- Food & beverage$2,113100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $541 |
| Mayne Pharma Commercial LLC | 31 | $468 |
| Exeltis, USA Inc. | 7 | $152 |
| Coopersurgical, Inc. | 7 | $137 |
| Astellas Pharma US Inc | 5 | $134 |
| Therapeuticsmd, Inc. | 8 | $128 |
| Sage Therapeutics, LLC | 4 | $108 |
| Aspira Women's Health Inc | 3 | $51 |
| Ascend Therapeutics US, LLC | 3 | $51 |
| Agile Therapeutics, Inc. | 2 | $41 |
| Millicent US Inc | 2 | $36 |
| Roche Diagnostics Corporation | 2 | $34 |
| BD | 2 | $34 |
| Cepheid | 1 | $31 |
| Mycovia Pharmaceuticals, Inc. | 1 | $29 |
| Lupin Inc. | 2 | $27 |
| Shield Therapeutics Inc | 1 | $23 |
| Bayer | 1 | $23 |
| Myovant Sciences Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Evofem Biosciences, Inc. | 1 | $14 |
| Channel Medsystems, Inc. | 1 | $11 |
How this compares
$2,113 in reported general payments places this provider in the 75th percentile of 3,784 obstetrics & gynecology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 136 | $13,105 |
| PremarinEstrogens, Conjugated | 20 | $6,987 |
| YuvafemEstradiol | 30 | $5,565 |
| Estradiol (Twice Weekly)Estradiol | 52 | $4,761 |
| PremproEstrogen,con/M-Progest Acet | 11 | $4,199 |
| VagifemEstradiol | 14 | $2,340 |
| ValacyclovirValacyclovir Hcl | 54 | $1,911 |
| ProgesteroneProgesterone, Micronized | 39 | $1,081 |
| Estradiol (Once Weekly)Estradiol | 20 | $1,072 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $350 |
| Lorazepam | 11 | $42 |
| Fluconazole | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Los Angeles
- Oleg BessLos Angeles$1.7M
- Michael FassettLos Angeles$1.2M
- Ritu SalaniLos Angeles$741K
- Malcolm MunroLos Angeles$609K
- Ramon YeraLos Angeles$296K
- Aela PaizLos Angeles$131K
- Radhika RibleLos Angeles$116K
- Carolyn HaunschildLos Angeles$97K
- Peyman BanooniBeverly Hills$9.2M
- Vellore BhupathyWhittier$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.